Sultan Darren, Goote Paige, Crowley Connor, Moon Victor, Kasabian Armen K, Knobel Denis
Division of Plastic and Reconstructive Surgery, Donald and Barbara Zucker School of Medicine at Hofstra University, Hempstead, New York, and Division of Plastic and Reconstructive Surgery, Northwell Health, Great Neck, New York.
Eplasty. 2024 May 7;24:e25. eCollection 2024.
Nearly half a million interbody fusions are estimated to be performed in the US each year, many of which involve complex reconstruction. The ability to limit seroma formation is vital to a seamless postoperative recovery.
A retrospective review was performed for patients undergoing fusion procedures along with flap reconstruction over a period of 20 months. Cohorts reflect a temporal practice shift where use of hydrolyzed collagen powder (HCP) was initiated for hypothesized seroma prevention. Outcomes and associated metrics were used for intergroup comparison.
The study included 76 patients, of whom 47 were treated with HCP and 29 were not. Control patients had significantly fewer postoperative seromas than experimental ones (6.9% vs 27.7%; = .03). The cohorts had no significant differences in time until final drain removal or in number of spinal levels involved (7.8 vs 7.1 days; = .33, 8.5 vs 8.4 levels; = .90). Rates of wound dehiscence, hematoma, or infection did not differ significantly between control and experimental patients (3.4% vs 12.8%, = .17; 0% vs 0%; and 6.9% vs 10.6%, = .58, respectively).
The use of HCP led to a 4-fold increase in postoperative seromas in patients undergoing spinal fusion with flap reconstruction. This was regardless of all analyzed demographic and procedural factors, with the exception of age, whereby control patients were found to be on average slightly younger than experimental counterparts.
据估计,美国每年进行近50万例椎间融合手术,其中许多涉及复杂重建。限制血清肿形成的能力对于术后顺利恢复至关重要。
对在20个月期间接受融合手术及皮瓣重建的患者进行回顾性研究。队列反映了一种时间上的实践转变,即开始使用水解胶原蛋白粉(HCP)以预防血清肿。使用结果及相关指标进行组间比较。
该研究纳入76例患者,其中47例接受HCP治疗,29例未接受。对照组患者术后血清肿明显少于试验组(6.9%对27.7%;P = 0.03)。两组在最终引流管拔除时间或涉及的脊柱节段数量上无显著差异(7.8天对7.1天;P = 0.33,8.5个节段对8.4个节段;P = 0.90)。对照组和试验组患者的伤口裂开、血肿或感染发生率无显著差异(分别为3.4%对12.8%,P = 0.17;0%对0%;6.9%对10.6%,P = 0.58)。
在接受脊柱融合及皮瓣重建的患者中,使用HCP导致术后血清肿增加了4倍。无论所有分析的人口统计学和手术因素如何,年龄除外,对照组患者平均比试验组患者略年轻。